Structural adjustment during intercalation of macrocyclic crown ether into LDH via swelling/restoration reaction: staging formation and mechanism insights
The present disclosure relates to peptidic compounds of Formula A, A-II, A-III, B, or C, or salt or solvate thereof, compositions thereof, and methods of use thereof. The compounds of the present disclosure are useful for targeting CXCR4 for purposes such as imaging and/or therapeutics.
[EN] RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN<br/>[FR] COMPOSÉS RADIOMARQUÉS CIBLANT L'ANTIGÈNE MEMBRANAIRE SPÉCIFIQUE DE LA PROSTATE
申请人:UNIV BRITISH COLUMBIA
公开号:WO2022126275A1
公开(公告)日:2022-06-23
The present invention relates to radiolabelled compounds for in vivo imaging or treatment of diseases or conditions characterized by expression of prostate-specific membrane antigen.
本发明涉及放射性标记化合物,用于体内成像或治疗由前列腺特异性膜抗原表达所特征的疾病或病况。
[EN] RADIOLABELLED PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITORS AND USE THEREOF<br/>[FR] INHIBITEURS D'ANTIGÈNE MEMBRANAIRE SPÉCIFIQUE DE LA PROSTATE (PSMA) RADIOMARQUÉS ET LEUR UTILISATION
申请人:3B PHARMACEUTICALS GMBH
公开号:WO2022123462A1
公开(公告)日:2022-06-16
The present disclosure is related to a compound of Formula 1 Wherein R is H or an effector domain which optionally comprises a linker.